NICE Recommends Takeda’s Exkivity for Exon 20 Mutation-Positive NSCLC

The UK’s National Institute for Health and Care Excellence (NICE) is recommending Takeda’s Exkivity (mobocertinib) for National Health Service (NHS) use in the treatment of adult patients with epidermal growth factor receptor exon 20 insertion mutation-positive locally advanced or metastatic nonsmall-cell lung cancer (NSCLC) who have received prior platinum-based chemotherapy.

NICE said it made the recommendation to fill an unmet clinical need as there is no standard treatment available for exon 20 insertion mutation-positive NSCLC.

Exkivity, taken as four capsules per day at home, works by targeting the mutation and slowing the growth of cancer cells.

The list price for Exkivity is more than $9,210 per pack of 112 capsules, each containing 40 mg of the active ingredient. The negotiated price for NHS use was not disclosed.